Literature DB >> 10684286

Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.

H Chen1, J He, S Fong, G Wilcox, C Wood.   

Abstract

Jembrana disease virus (JDV) is a bovine lentivirus genetically similar to bovine immunodeficiency virus; it causes an acute and sometimes fatal disease in infected animals. This virus carries a very potent Tat that can strongly activate not only its own long terminal repeat (LTR) but also the human immunodeficiency virus (HIV) LTR. In contrast, HIV Tat cannot reciprocally activate the JDV LTR (H. Chen, G. E. Wilcox, G. Kertayadnya, and C. Wood, J. Virol. 73:658-666, 1999). This indicates that in transactivation JDV Tat may utilize a mechanism similar to but not the same as that of the HIV Tat. To further study the similarity of JDV and HIV tat in transactivation, we first tested the responses of a series of HIV LTR mutants to the JDV Tat. Cross-transactivation of HIV LTR by JDV Tat was impaired by mutations that disrupted the HIV type 1 transactivation response element (TAR) RNA stem-loop structure. Our results demonstrated that JDV Tat, like HIV Tat, transactivated the HIV LTR at least partially in a TAR-dependent manner. However, the sequence in the loop region of TAR was not as critical for the function of JDV Tat as it was for HIV Tat. The competitive inhibition of Tat-induced transactivation by the truncated JDV or HIV Tat, which consisted only of the activation domain, suggested that similar cellular factors were involved in both JDV and HIV Tat-induced transactivation. Based on the one-round transfection assay with HIV tat mutant proviruses, the cotransfected JDV tat plasmid can functionally complement the HIV tat defect. To further characterize the effect of JDV Tat on HIV, a stable chimeric HIV carrying the JDV tat gene was generated. This chimeric HIV replicated in a T-cell line, C8166, and in peripheral blood mononuclear cells, which suggested that JDV Tat can functionally substitute for HIV Tat. Further characterization of this chimeric virus will help to elucidate how JDV Tat functions and to explain the differences between HIV and JDV Tat transactivation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684286      PMCID: PMC111760          DOI: 10.1128/jvi.74.6.2703-2713.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Detection of specific human immunodeficiency virus type 1 Tat-TAR complexes in the presence of mild denaturing conditions.

Authors:  S E Fong; P Smanik; T Thais; M C Smith; S R Jaskunas
Journal:  J Virol Methods       Date:  1997-06       Impact factor: 2.014

2.  Tat is required for efficient HIV-1 reverse transcription.

Authors:  D Harrich; C Ulich; L F García-Martínez; R B Gaynor
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Nucleotide sequence analysis of Jembrana disease virus: a bovine lentivirus associated with an acute disease syndrome.

Authors:  B J Chadwick; R J Coelen; G E Wilcox; L M Sammels; G Kertayadnya
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

4.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

Review 5.  Tat, Tat-associated kinase, and transcription.

Authors:  K T Jeang
Journal:  J Biomed Sci       Date:  1998       Impact factor: 8.410

6.  Dual role of HIV Tat in regulation of apoptosis in T cells.

Authors:  T W McCloskey; M Ott; E Tribble; S A Khan; S Teichberg; M O Paul; S Pahwa; E Verdin; N Chirmule
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

7.  Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain.

Authors:  C A Parada; R G Roeder
Journal:  Nature       Date:  1996-11-28       Impact factor: 49.962

8.  HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals.

Authors:  P D Katsikis; M E García-Ojeda; J F Torres-Roca; D R Greenwald; L A Herzenberg; L A Herzenberg
Journal:  Int Immunol       Date:  1997-06       Impact factor: 4.823

9.  High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection.

Authors:  R Mariani; F Kirchhoff; T C Greenough; J L Sullivan; R C Desrosiers; J Skowronski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

10.  Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease.

Authors:  F Kirchhoff; P J Easterbrook; N Douglas; M Troop; T C Greenough; J Weber; S Carl; J L Sullivan; R S Daniels
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

View more
  4 in total

1.  A single intermolecular contact mediates intramolecular stabilization of both RNA and protein.

Authors:  Valerie Calabro; Matthew D Daugherty; Alan D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-27       Impact factor: 11.205

2.  Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.

Authors:  Baode Xie; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Comparative functional analysis of Jembrana disease virus Tat protein on lentivirus long terminal repeat promoters: evidence for flexibility at its N-terminus.

Authors:  Yang Su; Gang Deng; Yuanming Gai; Yue Li; Yang Gao; Jiansen Du; Yunqi Geng; Qimin Chen; Wentao Qiao
Journal:  Virol J       Date:  2009-10-28       Impact factor: 4.099

4.  Potential of polylactic-co-glycolic acid (PLGA) for delivery Jembrana disease DNA vaccine Model (pEGFP-C1-tat).

Authors:  Lalu Unsunnidhal; Raden Wasito; Erif Maha Nugraha Setyawan; Ziana Warsani; Asmarani Kusumawati
Journal:  J Vet Sci       Date:  2021-08-30       Impact factor: 1.672

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.